AstraZeneca Pharma gets import, market permission from DCGI for Dapagliflozin film coated tablet

06 Jul 2020 Evaluate

AstraZeneca Pharma India has received Import and Market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India (DCGI) for Dapagliflozin film coated tablet 10mg.

Dapagliflozin film coated tablet 10mg is additional indication in adults for the treatment of heart failure with reduced ejection fraction. The receipt of this Import and Market permission paves way for launch of Dapagliflozin film coated tablet 10mg in India, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma I Share Price

9138.35 -7.10 (-0.08%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×